Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06609005 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
A Phase 1 study of Advanced Metastatic Castration Resistant Prostate Cancer, sponsored by Shenzhen Ionova Life Sciences Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
- 17
- Study locations
NCT06609005: Recruiting Phase 1 study of Advanced Metastatic Castration Resistant Prostate Cancer, sponsored by Shenzhen Ionova Life Sciences Co..
NCT06609005 is a Phase 1 study of Advanced Metastatic Castration Resistant Prostate Cancer that is actively recruiting participants, run by Shenzhen Ionova Life Sciences Co.. The registered enrollment target is 84 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher). The trial reports 17 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06609005, a Phase 1 study of Advanced Metastatic Castration Resistant Prostate Cancer, is actively recruiting participants, sponsored by Shenzhen Ionova Life Sciences Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.
Primary Outcome
The highest dose level at which at least 6 patients have been treated and less than 33% of patients experienced a DLT.
Conditions Studied
Interventions
- DRUG INV-9956
Study Locations (17)
California
- Hoag Family Cancer Institute - Newport Beach
- UC Irvine Medical Center - Orange
Texas
- Next Oncology - Houston - Houston
- UT Health - San Antonio
Zhejiang
- The First Affiliated Hospital, School of Medicine, Zhejiang University - Hangzhou
- Zhejiang Provincial People's Hospital - Hangzhou
Arizona
- Honor Health - Scottsdale
Virginia
- NEXT Oncology - Fairfax
Washington
- Summit Cancer Centers - Spokane
Fujian
- The First Affiliated Hospital of Fujian Medical University - Fuzhou
He'Nan
- He'nan Cancer Hospital - Zhengzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2028-01-17 |
| Phase | Phase 1 |
What NCT06609005 shows while recruiting
NCT06609005 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher).
The record links to 1 condition, with Advanced Metastatic Castration Resistant Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which INV-9956 is the first listed.
NCT06609005 lists 17 locations in 14 states (California, Texas, Zhejiang).
Frequently Asked Questions
What is clinical trial NCT06609005 about?
NCT06609005 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer". This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.
What is the current status of trial NCT06609005?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2025-01-23. Estimated completion is 2028-01-17.
What conditions does trial NCT06609005 study?
This clinical trial studies the following conditions: Advanced Metastatic Castration Resistant Prostate Cancer.
What interventions are being tested in trial NCT06609005?
The interventions under investigation include: INV-9956 (DRUG).
Who is sponsoring clinical trial NCT06609005?
This trial is sponsored by Shenzhen Ionova Life Sciences Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06609005 being conducted?
This trial has 17 study locations across Arizona, California, Texas, Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Metastatic Castration Resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06609005's enrollment target sits among peer trials
84 660th of 2000 higher than 1,336 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI